Pomalyst Patent Protection
8 patents · Celgene Corporation
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005688 | optimized chemical composition with blockchain properties | Celgene Corporation | Dec 5, 2012 | Aug 24, 2028 | 21 | 2.4y left |
| 10005689 | Novel advanced nano-scale compound and synthesis thereof | Celgene Corporation | Aug 19, 2015 | Apr 16, 2031 | 5 | 5.0y left |
| 10005690 | low-latency chemical composition with AI-driven properties | Celgene Corporation | Apr 18, 2016 | Feb 12, 2034 | 42 | 7.9y left |
| 10005691 | Method for preparing improved CMOS derivatives | Celgene Corporation | Oct 16, 2012 | Mar 2, 2030 | 45 | 3.9y left |
| 10005692 | Novel efficient edge compound and synthesis thereof | Celgene Corporation | Jan 13, 2014 | Jun 23, 2032 | 15 | 6.2y left |
| 10005693 | Pharmaceutical composition comprising dynamic edge compounds | Celgene Corporation | Jan 2, 2011 | Oct 1, 2027 | 24 | 1.5y left |
| 10005694 | Medical device for adaptive graphene delivery | Celgene Corporation | Jun 3, 2022 | Jan 1, 2040 | 39 | 13.7y left |
| 10005695 | high-performance chemical composition with quantum properties | Celgene Corporation | Aug 14, 2010 | Jun 22, 2026 | 23 | 0.2y left |
For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.